NCT01483820View on ClinicalTrials.gov

Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
NeuroblastomaMedulloblastoma
Interventions
DRUG

TPI 287

Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 21-day cycle.

Trial Locations (8)

28204

Levine Children's Hospital, Charlotte

29425

Medical University of South Carolina, Charleston

32806

Arnold Palmer Hospital for Children- MD Anderson, Orlando

49503

Helen DeVos Children's Hospital, Grand Rapids

63104

Cardinal Glennon Children's Medical Center, St Louis

64108

Children's Mercy Hospitals and Clinics, Kansas City

92123

Rady Children's Hospital, San Diego

06106

Connecticut Children's Hospital, Hartford

Sponsors

Collaborators (1)

Cortice Biosciences, Inc.
All Listed Sponsors
collaborator

Cortice Biosciences, Inc.

INDUSTRY

lead

Giselle Sholler

OTHER

NCT01483820 - Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma | Biotech Hunter | Biotech Hunter